Prostate cancer
Conditions
Interventions
Surgical castration group:None
Medical castration group:None
Sponsors
The First Affiliated Hospital of Anhui Medical University
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1.Patients pathologically diagnosed with prostate cancer following abnormal findings on serum PSA, testosterone levels, and digital rectal examination (DRE), and confirmed by transrectal ultrasound (TRUS)-guided prostate needle biopsy; 2.Patients meeting the criteria for very high-risk prostate cancer, defined as having any one of the following: a predominant Gleason pattern 5, >=4 biopsy cores with a Gleason score >=8, or a clinical stage of >=T3b, with no evidence of distant metastasis; 3.Preoperative imaging (e.g., pelvic MRI, contrast-enhanced CT, or PET-CT) indicating that the local lesion is resectable; 4.Patients diagnosed with androgen-dependent prostate cancer prior to treatment initiation; 5.No prior history of radiotherapy or endocrine therapy, and no contraindications to androgen deprivation therapy (ADT); 6.Patients with good compliance, standardized treatment protocols, and complete follow-up data
Exclusion criteria
Exclusion criteria: 1.Patients with histopathological or cytological evidence of neuroendocrine prostate cancer, including small cell carcinoma; 2.Patients diagnosed with a second primary malignancy; 3.Patients with contraindications to surgery due to active viral hepatitis, other chronic liver diseases, or cardiopulmonary insufficiency; 4.Patients who fail to adhere to medical instructions, are uncooperative with follow-up, or have incomplete follow-up data; 5.Any other patients deemed unsuitable for study participation by the investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Biochemical recurrence;Time to biochemical recurrence;Progression to castration - resistant prostate cancer (CRPC);Time to progression to castration - resistant prostate cancer (CRPC); | — |
Secondary
| Measure | Time frame |
|---|---|
| General Demographic Data (Age, BMI, etc.);Baseline prostate - specific antigen (PSA);Pathological characteristics (prostate volume, Gleason score, pathological stage, lymph node metastasis, etc.);Hospitalization - related information (surgical time, blood loss, length of hospital stay, etc.);Total cost;Persistent prostate - specific antigen (PSA); | — |
Countries
China
Contacts
Public ContactZhou Jun
The First Affiliated Hospital of Anhui Medical University
Outcome results
None listed